Skip to main content

Table 3 The correlations between CDH13 methylation and clinicopathological features

From: Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis

 

Studies

Overall OR (95 % CI)

I2; p

P value

p (Egger’s test)

Patients

Gender

     

Male

Female

 

5

1.46 (0.99–2.15)

0.0 %; 0.496

0.053

0.085

437

163

Grade

     

High-grade

Low-grade

 

4

2.22 (1.43–3.43)

0.0 %; 0.641

<0.001

0.613

169

284

Stage

     

MIBC

NMIBC

 

5

3.42 (1.72–6.80)

59.0 %; 0.045

<0.001

0.279

174

345

Number

     

Multiple

Single

 

5

1.45 (1.03–2.04)

0.0 %; 0.779

0.032

0.038

319

281

  1. MIBC muscle invasive bladder cancer (stages T2–T4), NMIBC non-muscle invasive bladder cancer (stages Ta – T1), low-grade tumor grade ≤ 2, high-grade tumor grade of 3
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us